Physicians' Academy for Cardiovascular Education

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

ACC 2018 Besides the expected effect on prevention of MI, alirocumab was also associated with a decrease of total mortality. In addition, the results give insight in the group of patients that will benefit the most from this drug.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Prof. Wouter Jukema - cardiologist, Leiden University Medical Center, Leiden, The Netherlands

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Read more about the results of the ODYSSEY OUTCOMES trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: